期刊文献+

前列腺癌间歇内分泌治疗依从性及其影响因素的研究 被引量:3

Study on patient compliance to intermittent endocrine therapy in prostate cancer
暂未订购
导出
摘要 目的探讨前列腺癌间歇内分泌治疗(IHT)依从性影响因素。方法纳入我院门诊行抗雄激素治疗的前列腺癌患者67例,采用自制量表评价患者依从性,Logistic回归分析各影响因素对治疗依从性的影响。结果67例中24例患者(35.82%)治疗依从性差;Logistic回归分析显示,自费、独居和对副作用耐受性差是三个影响治疗依从性的最主要因素。结论重视前列腺癌患者的社会和家庭支持是提高依从性的关键。 Objective To investigate the factors impacting the patient compliance to intermittent endocrine therapy ( IHT) in prostate cancer. Methods 67 out-patients with Prostate cancer were enrolled in this study. All patients were received IHT treatment. Their compliance were evaluated with self-made scale. Logistic regression was used to analyze the effect of all factors considered into this study for IHT. Results 24 patients(35.82% ) had poor compliance. Logistic regression showed three factors which impacting patient compliance most , including medicine at their own expense , living alone and poor tolerance to side effects. Conclusion The key to improve patient compliance is to pay more attention to the support from society and family for patients.
出处 《实用医院临床杂志》 2009年第5期44-45,共2页 Practical Journal of Clinical Medicine
关键词 前列腺癌 间歇内分泌治疗 依从性 Prostate cancer Intermittent endocrine therapy Compliance
  • 相关文献

参考文献3

  • 1中华医学会泌尿外科学分会.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2007:64-69.
  • 2Fluchter SH, Weiser R, Gamper C. The role of hormonal treatment in prostate cancer [ J ]. Recent Resutls Cancer Res, 2007,175 ( 2 ) : 211 - 237.
  • 3孔垂泽.前列腺癌的间歇内分泌治疗[J].临床外科杂志,2008,16(2):95-98. 被引量:7

二级参考文献19

  • 1Huggins C, Hodges CV, Valett BS, et al. Studies on prostatic cancer: effect of castration,of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate [ J ]. Cancer Res, 1941, 18:293-298.
  • 2Gleave M, Goldenberg SL, Bruchovsky N, et al. Intermittent androgen suppression for prostate cancer: rationale and clinical experience [ J ]. Prostate Cancer Prostatic Dis, 1998,1 (6) :289-296.
  • 3Goldenberg SL, B ruchovsky N, Gleave ME, et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report [ J ]. Urology, 1995,45 (5) :839-844.
  • 4Rashid MH, Chaudhary UB. Intermittent androgen deprivation therapy for prostate cancer [ J ]. Oneologist ,2004,9 ( 3 ) :295-301.
  • 5Prapotnich D, Fizazi K, Escudier B, et al. A 10 - year clinical experience with intermittent hormonal therapy for prostate cancer [ J ] . Eur Uro1,2003,43 (3) :233-239.
  • 6Prostate Cancer TfialistsColleborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients [J]. Lancet,1995,346(8970) :265-269.
  • 7Laitinen S, Martikainen PM, Tammela TL, et al. Cellular changes in prostate cancer cells induced by intermittent androgen suppression [ J ]. Eur Urol,2007,52(3 ) :725-732.
  • 8Lee SO, Dutt SS, Nadiminty N, et al. Development of an androgen - dep rivation induced and androgen suppressed human prostate cancer cell line [ J ]. Prostate,2007,67 ( 12 ) : 1293-1300.
  • 9Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen - independent regulation of prostate -specific antigen gene in the LNCaP prostate tumour modal [ J ]. J Steroid Bioehem Mol Bio1,1996,58(2) :139-146.
  • 10Akakura K,Bruehovsky N,Rennie PS,et al. Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM -2 (clusterin) gene in the Shionogi carcinoma [J]. J Steroid Biochem Mol Bio1,1996,59(5 -6):501-511.

共引文献8

同被引文献29

  • 1韩淑英,史文峰.重视沟通技巧 改善医患关系[J].中国卫生质量管理,2003,10(5):35-36. 被引量:7
  • 2吴乾.恶性肿瘤患者知情同意中存在的问题及对策[J].中国现代药物应用,2009,3(5):197-198. 被引量:2
  • 3张铁山,李殿富.医患沟通中患者的信息认知[J].医学与哲学,2004,25(9):25-27. 被引量:19
  • 4周守君,顾慧,安媛媛.肿瘤病人医疗服务中的医患沟通路径研究[J].中国医院管理,2007,27(7):32-34. 被引量:15
  • 5GLEAVE M, GOLDENBERG SL, BRUCHOVSKY N, et al. Intermittent androgen suppression for prostate cancer rationale and clinical experience [J]. Prostate Cancer Prostatic Dis, 1998,1(6) : 189-296.
  • 6GOLDENBERG SL, BRUCHOVSKY N, G LEAVE ME, et al. Intermittent androgen suppression in the treatment Of prostate cancer a preliminary report [J]. Urology, 1995, 45 (5) :839-844.
  • 7RASHID MH, CHAUDHARY UB. Intermittent androgen deprivation therapy for prostate cancer [J]. Oncologist,2004,9 (3) :295-301.
  • 8PRAPOTNICH D, FIZAZI K, ESCUDIER B,et al. A 10year clinical experience with intermittent homonal therapy for prostate cancer [J]. EurUrol,2003, 43(3) :233-239.
  • 9GROSSFELD GD, CHAUDHARY UB, REESE DM, et al. Intermittent androgen deprivation: update of cycling characteristics in peatients without clinically apparent metastatic prostate cancer [J]. Urology, 2001,58(2):240-245.
  • 10MIYAMOTOH, MESSING EM, CHANG C. Androgen deprivation therapy for prostate cancer: current and future prospects[J]. Prostate,2004,61:332.

引证文献3

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部